Xilio Therapeutics, Inc. (XLO)
Largest Insider Buys in Sector
XLO Stock Price History Chart
XLO Stock Performance
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Insider Activity of Xilio Therapeutics, Inc.
Over the last 12 months, insiders at Xilio Therapeutics, Inc. have bought $368,790 and sold $4,240 worth of Xilio Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Xilio Therapeutics, Inc. have bought $15.99M and sold $4,240 worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $1.48M.
The last purchase of 485,250 shares for transaction amount of $368,790 was made by GILEAD SCIENCES, INC. (10 percent owner) on 2024‑04‑02.
List of Insider Buy and Sell Transactions, Xilio Therapeutics, Inc.
| 2024-04-02 | GILEAD SCIENCES, INC. | 10 percent owner | 485,250 0.9047% | $0.76 | $368,790 | -26.35% | ||
| 2024-02-08 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 1,000 0.0034% | $0.64 | $640 | +74.17% | |
| 2024-01-12 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 2,100 0.0088% | $0.83 | $1,743 | +28.49% | |
| 2024-01-11 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 2,135 0.0083% | $0.87 | $1,857 | +12.64% | |
| 2021-12-10 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 25,000 0.0858% | $9.65 | $241,202 | -70.24% | ||
| 2021-12-09 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 4,011 0.0145% | $9.84 | $39,485 | -69.23% | ||
| 2021-12-08 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 13,458 0.0484% | $9.62 | $129,474 | -68.51% | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP | 10 percent owner | 312,500 1.1398% | $16.00 | $5M | -76.08% | ||
| 2021-10-26 | RiverVest Venture Fund IV, L.P. | 10 percent owner | 250,000 0.9119% | $16.00 | $4M | -76.08% | ||
| 2021-10-26 | Rock Springs Capital Management LP | 10 percent owner | 500,000 1.8238% | $16.00 | $8M | -76.08% | ||
| 2021-10-26 | Flynn James E | 10 percent owner | 387,500 1.4134% | $16.00 | $6.2M | -76.08% | ||
| 2021-10-26 | BAY CITY CAPITAL LLC | 10 percent owner | 312,500 1.1398% | $16.00 | $5M | -76.08% | ||
| 2021-10-26 | Atlas Venture Fund XI, L.P. | 10 percent owner | 187,500 0.6839% | $16.00 | $3M | -76.08% |
Insider Historical Profitability
| GILEAD SCIENCES, INC. | 10 percent owner | 7345473 21.3076% | $0.91 | 1 | 0 | |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 734546 2.6683% | $0.91 | 1 | 3 | <0.0001% |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2805413 10.1908% | $0.91 | 3 | 0 | <0.0001% |
| SV7 Impact Medicine Fund LP | 10 percent owner | 1613632 5.8616% | $0.91 | 1 | 0 | <0.0001% |
| RiverVest Venture Fund IV, L.P. | 10 percent owner | 1441444 5.2361% | $0.91 | 1 | 0 | <0.0001% |
| Rock Springs Capital Management LP | 10 percent owner | 1256472 4.5642% | $0.91 | 1 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 1143972 4.1555% | $0.91 | 1 | 0 | <0.0001% |
| BAY CITY CAPITAL LLC | 10 percent owner | 1129490 4.1029% | $0.91 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Bain Capital Life Sciences Investors Llc | $3.03M | 7.6 | 2.81M | 0% | +$0 | 0.3 | |
| Fidelity Investments | $2.06M | 5.17 | 1.91M | 0% | +$0 | <0.0001 | |
| RiverVest | $1.56M | 3.91 | 1.44M | 0% | +$0 | 19.12 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $1.56M | 3.9 | 1.44M | 0% | +$0 | 0.04 | |
| Atlas Venture Life Science Advisors Llc | $1.07M | 2.69 | 992,912 | -64.02% | -$1.91M | 0.1 | |
| The Vanguard Group | $974,734.00 | 2.45 | 902,531 | 0% | +$0 | <0.0001 | |
| Balyasny Asset Management Llc | $365,625.00 | 0.92 | 338,542 | New | +$365,625.00 | <0.01 | |
| Renaissance Technologies | $269,000.00 | 0.68 | 249,446 | +18.95% | +$42,861.68 | <0.0001 | |
| Morgan Stanley | $239,657.00 | 0.6 | 221,905 | +74.36% | +$102,211.03 | <0.0001 | |
| Fil Ltd | $236,201.00 | 0.59 | 218,705 | 0% | +$0 | <0.0001 | |
| Geode Capital Management | $91,650.00 | 0.23 | 84,826 | 0% | +$0 | <0.0001 | |
| Bridgeway Capital Management | $76,767.00 | 0.19 | 71,081 | -54.28% | -$91,151.43 | <0.01 | |
| Millennium Management LLC | $75,814.00 | 0.19 | 70,198 | +131.29% | +$43,034.85 | <0.0001 | |
| BlackRock | $48,983.00 | 0.12 | 45,355 | -3.22% | -$1,627.55 | <0.0001 | |
| SevenBridge Financial Group | $36,580.00 | 0.08 | 31,000 | New | +$36,580.00 | 0.01 | |
| Prelude Capital | $31,860.00 | 0.08 | 29,500 | New | +$31,860.00 | <0.01 | |
| Fny Investment Advisers Llc | $29,000.00 | 0.08 | 27,500 | New | +$29,000.00 | 0.02 | |
| Northern Trust | $19,222.00 | 0.05 | 17,798 | 0% | +$0 | <0.0001 | |
| Summit Trail Advisors | $17,280.00 | 0.04 | 16,000 | New | +$17,280.00 | <0.0001 | |
| State Street | $16,945.00 | 0.04 | 15,690 | 0% | +$0 | <0.0001 | |
| Charles Schwab | $12,879.00 | 0.03 | 11,925 | 0% | +$0 | <0.0001 | |
| Tower Research Capital | $12,045.00 | 0.03 | 11,153 | -20.19% | -$3,047.70 | <0.0001 | |
| JPMorgan Chase | $2,964.00 | 0.01 | 2,744 | -3.96% | -$122.06 | <0.0001 | |
| Key Financial, Inc. | $896.00 | <0.01 | 830 | 0% | +$0 | <0.0001 | |
| UBS | $217.00 | <0.01 | 201 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $1,000.00 | <0.01 | 533 | +13.89% | +$121.95 | <0.0001 | |
| Qube Research & Technologies | $4.00 | <0.01 | 4 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $117.00 | <0.01 | 108 | +1.89% | +$2.17 | <0.0001 |